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ABSTRACT
Burkitt lymphoma is a fast-growing tumor derived from germinal center B cells. 
It is mainly treated with aggressive chemotherapy, therefore novel therapeutic 
approaches are needed due to treatment toxicity and developing resistance. 
Disturbance of red-ox homeostasis has recently emerged as an efficient antitumor 
strategy. Peroxiredoxins (PRDXs) are thioredoxin-family antioxidant enzymes 
that scavenge cellular peroxides and contribute to red-ox homeostasis. PRDXs are 
robustly expressed in various malignancies and critically involved in cell proliferation, 
differentiation and apoptosis. To elucidate potential role of PRDXs in lymphoma, we 
studied their expression level in B cell-derived primary lymphoma cells as well as 
in cell lines. We found that PRDX1 and PRDX2 are upregulated in tumor B cells as 
compared with normal counterparts. Concomitant knockdown of PRDX1 and PRDX2 
significantly attenuated the growth rate of lymphoma cells. Furthermore, in human 
Burkitt lymphoma cell lines, we isolated dimeric 2-cysteine peroxiredoxins as targets 
for SK053, a novel thiol-specific small-molecule peptidomimetic with antitumor 
activity. We observed that treatment of lymphoma cells with SK053 triggers formation 
of covalent PRDX dimers, accumulation of intracellular reactive oxygen species, 
phosphorylation of ERK1/2 and AKT and leads to cell cycle arrest and apoptosis. 
Based on site-directed mutagenesis and modeling studies, we propose a mechanism            
of SK053-mediated PRDX crosslinking, involving double thioalkylation of active site 
cysteine residues. Altogether, our results suggest that peroxiredoxins are novel 
therapeutic targets in Burkitt lymphoma and provide the basis for new approaches 
to the treatment of this disease.
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INTRODUCTION
Burkitt lymphoma (BL) is a relatively rare in 
Western countries, yet highly aggressive germinal B 
cell-derived malignancy. Intensive chemotherapy is 
the mainstay of treatment, however considerable drug 
toxicity prompts the need to develop novel less toxic and 
efficient approaches. One of the therapeutic challenges 
is extremely fast growth of BL – short doubling time 
and proliferation fraction of nearly 100%. Rapidly 
proliferating cells have been reported to have increased 
levels of reactive oxygen species (ROS) [1, 2], rendering 
these cells reliant on specific antioxidant enzymes 
[3, 4]. Several groups of enzymes account for red-ox 
balance, including peroxiredoxins (PRDXs) belonging 
to thioredoxin (TRX) family. Currently, little is known 
about the role of PRDXs in B cell-derived malignancies. 
Notably, PRDX1 expression was seen increased upon B 
cell activation and was high in lymphomas [5].
PRDXs are enzymes that utilize conserved Cys 
residues to catalyze peroxides reduction. In mammals, there 
are six PRDXs, classified depending on the number and 
localization of the catalytic Cys residues into 3 subtypes: 
typical 2-Cys (PRDX1–4), atypical 2-Cys (PRDX5), and 
1-Cys (PRDX6) peroxiredoxins. For all subtypes, there 
are two steps in peroxide reduction. Firstly, the thiol of 
peroxidatic Cys attacks the peroxide oxygen and becomes 
oxidized to sulfenic acid. Secondly, the sulfenic acid is 
attacked by a resolving Cys thiol, and a disulfide bond is 
formed. In typical 2-Cys PRDXs, which are head-to-tail 
functional homodimers, the resolving Cys comes from 
the C-terminus of the other monomer. Atypical 2-Cys and 
1-Cys PRDXs, with resolving Cys in the same subunit or 
coming from other proteins or peptides, respectively, are 
functional monomers. Finally, to complete the catalytic 
cycle, the disulfide bond formed in the PRDX active site is 
reduced by the TRX-TRXR-NADPH system [6, 7].
Hydrogen peroxide works as a second messenger; 
therefore, its generation and removal are strictly regulated. 
Although other groups of enzymes such as catalases and 
glutathione peroxidases also scavenge hydrogen peroxide, 
PRDXs are crucial antioxidants due to their abundance and 
prevalence in various cellular compartments. PRDXs also 
directly interact with a variety of key signaling proteins, 
such as MAPKs [8], c-ABL [9], c-MYC [10], or tyrosine 
phosphatase PTEN [11]. They protect redox-sensitive 
catalytic cysteine residues of phosphatases and suppress 
MAPK signaling and senescence [12].
The expression levels of PRDXs have been 
studied in a number of malignancies. For example, in 
lung [13], ovarian [14], and colorectal [15] cancers, 
high PRDX1 levels predict worse response to therapy. 
Yet, in a subtype of breast cancer PRDX1 is a biomarker 
of favorable prognosis [16]. Correspondingly, at the 
early stages of leukemogenesis, PRDX2 inhibits the 
proliferation of hematopoietic precursor cells [17]. 
On the other hand, PRDXs are highly expressed in 
promyelocytic leukemia cells and have cytoprotective, 
growth-promoting functions [18]. These findings 
highlight growing demand for small molecules targeting 
TRX-like enzymes as putative anti-tumor therapeutics. 
Such an example is adenanthin, a diterpenoid plant 
metabolite, which inhibits TRX-like enzymes and exerts 
anti-leukemic activity [18, 19].
We have recently designed a peptidomimetic 
inhibitor, SK053, aimed to bind TRX (compound 19a in 
[20]). This compound inhibits the activity of TRX and 
exerts cytostatic/cytotoxic effect with a clear preference 
towards rapidly proliferating cells, including murine 
(EMT6, Panc02, CT26) and human (Raji, Ramos, K562) 
tumor cell lines. Importantly, SK053 demonstrates 
antitumor activity in mice with no evidence of systemic 
toxicity [20]. In BL cell line Raji, SK053 induces 
endoplasmic reticulum stress-mediated apoptosis [21]. The 
inhibitor was designed to carry two electrophilic centers. 
The putative mechanism of the inhibitor binding to TRX 
involves a double thioalkylation of the two catalytic 
cysteine residues. In this study, using a biotin affinity 
probe-labeling approach, we identified typical 2-Cys 
PRDXs as targets for SK053 in human BL cell lines.
RESULTS
TRX-like antioxidant enzymes are upregulated 
in B cell-derived lymphoma primary cells and 
cell lines
To gain deeper insight into the PRDX-TRX-
TRXR antioxidant system in B cell malignancies, 
we analyzed the deposited microarray data [22] on 
the expression of PRDX1–4, TRX1, and TRXR1. 
The data contained malignant B cells derived from 
BL and diffuse large B-cell lymphoma (DLBCL) 
patients and normal B cell subsets. We observed 
upregulated expression of PRDX1, PRDX2, and TRX1 
in malignant cells. PRDX2 expression was extremely 
high in BL (Figure 1A, Supplementary Tables S1 
and S2). Considering that TRX1 is already a known 
therapeutic target in lymphoma [23], we focused on 
two PRDX cytoplasmic isoforms, PRDX1 and PRDX2. 
Immunohistochemistry of primary BL revealed robust 
membrane and cytoplasmic staining for both PRDX1 
and PRDX2 (Figure 1B). To extend these observations, 
we analyzed the expression of PRDX1 and PRDX2 in a 
panel of B cell-derived tumor cell lines. In the majority 
of cell lines, both PRDX1 and PRDX2 were highly 
expressed, as compared with normal B cells (Figure 1C, 
1D Supplementary Figure S1). Altogether, the above 
results demonstrate increased expression of TRX-like 
antioxidant enzymes in lymphoma cell lines as well as 
in primary cells from lymphoma patients.
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Figure 1: PRDX1 and PRDX2 are upregulated in lymphoma cells. A. Analysis of the expression of PRDX1-4, TRX1, TRXR1, 
in the data set E-GEOD-12453 deposited in the ArrayExpress database. The expression is analyzed in 5 sub-populations of normal B 
cells (left-hand) and in malignant B-cell derived DLBCL and BL cells (right-hand). B. IHC staining of lymph nodes (LNs) with reactive 
follicular hyperplasia (left panel) and representative BL cells for PRDX1 and PRDX2 (EnVision stain, 20x). In the right panel, insertions 
in the upper right corners have higher magnification (60x) of BL tissue stained with anti-PRDX1 and PRDX2, respectively. C. qRT-PCR 
analysis of the PRDX1 and PRDX2 gene expression in B cell-derived tumor cell lines and four CD19+ control B cells. qPCR data were 
normalized to housekeeping genes, RPL29 and β-2-microglobulin. The fold change is displayed on a log2 scale. Mean values from two 
independent experiments are shown, the bars indicate the standard error of the mean (SEM). D. Representative Western blot for the PRDX1 
and PRDX2 protein levels in B cell-derived tumor cell lines and CD19+ control B cells obtained from 4 healthy donors.
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Downregulation of PRDX1 and 2 decreases the 
proliferation and survival of lymphoma cells
Next, we studied the effects of PRDX1 
downregulation on the growth rate and survival of BL Raji 
cells which express PRDX2, and of a Raji subline, (Raji-
sub) [24], which we identified not to express PRDX2. 
In Raji-sub cells, partial reduction of the PRDX1 level 
(shRNA1) slightly reduced the growth rate, while more 
pronounced inhibition of PRDX1 expression (shRNA2) 
resulted in a significant inhibition of cell growth (Figure 
2A) and the induction of apoptosis, as measured by 
PARP cleavage (Figure 2B). In Raji cells the silencing 
of a single PRDX1 or PRDX2 gene slightly diminished 
cell proliferation. However, the effects of concomitant 
PRDX1 and PRDX2 knockdown resulted in ERK1/2 
phosphorylation, an increase in p21, and the induction of 
apoptosis (Figure 2C, 2D). Moreover, in Raji cells with 
a reduced PRDX1 level, we observed decreased DNA 
synthesis and G0/G1 cell cycle arrest (Figure 2D). In 
Namalwa, another BL cell line, PRDX1, but not PRDX2, 
knockdown alone already significantly reduced cell 
growth rate. Importantly, the growth was further blunted in 
cells with simultaneous PRDX1 and PRDX2 knockdown. 
As in Raji cells, PRDX1 downregulation reduced the rate 
of DNA synthesis (Supplementary Figure S2). Altogether, 
these results demonstrate that concomitant PRDX1 and 
PRDX2 knockdown significantly attenuates growth rate 
of BL cells.
PRDX1 is a target for SK053
Considering the elevated levels of TRX-like 
enzymes as well as their pro-survival role in lymphoma 
cells, we searched for candidate compounds for their 
pharmacologic inhibition. We have previously reported 
on the synthesis of the thiol-specific small molecule 
peptidomimetic with antitumor activity, SK053. Here, 
we have found that BL cell lines are sensitive to SK053, 
with an LC
50
 ranging from 7 μM for the Namalwa up to 
almost 20 μM for Bjab cells. Importantly, normal germinal 
center B cells (GC B cells) isolated from human tonsils 
were more resistant to SK053 (LC
50
 > 60 μM), indicating 
selectivity towards malignant B cells (Figure 3A).
To identify targets for SK053 in BL cells, we 
synthesized biotin-tagged derivative of SK053 (SK-
bio) and an inactive, biotinylated analogue that lacks 
the electrophilic double bond (SK-in), which was used 
as a negative control (Figure 3B, Supplementary Figure 
S3). Only the active, SK-bio preserved cytostatic/
cytotoxic activity (Supplementary Figure S4). A band of 
approximately 20 kDa was detected in a silver-stained 
gel only for cells incubated with active SK-bio (Figure 
3C). The protein was identified by MS as PRDX1, with > 
90% of sequence coverage. Furthermore, in a collection 
of tryptic peptides, we searched for a modification of 
540 Da, corresponding to the mass of SK053, after the 
first addition reaction, and the modification of 466 Da, 
which corresponds to the part of SK053 after the addition 
and elimination of the leaving group, according to the 
previously described mechanism (Scheme 3 in [20]). We 
found the tryptic peptide, containing Cys173, with a mass 
modification of 466 Da. The fragmentation of the peptide 
confirmed that the modification is on Cys173 (Figure 3D). 
Immunoblotting revealed that PRDX1, but neither TRX1 
nor TRXR1, is present in the beads eluates from cells 
treated with SK-bio (Figure 3E, Supplementary Figure 
S5). All of the above results demonstrate that SK053 
covalently binds to PRDX1 in Raji cells.
SK053 crosslinks typical 2-Cys PRDXs dimers
Next, we monitored the levels of PRDX1 in Raji 
cells after SK-bio treatment. As shown in Figure 4A, we 
observed a time-dependent accumulation of the additional 
protein band recognized with anti-PRDX1 antibody, with 
a mass corresponding to PRDX1 dimer. The band was also 
observed in cells treated with unlabeled SK053 (Figure 
4B). As the protein lysates were resolved under denaturing 
and reducing conditions, the above results suggest that 
the higher-molecular weight band is covalent and not 
disulfide-linked. To further expand on this observation, we 
tested the levels of monomers and dimers of all six PRDXs 
in Raji and Ramos cells that were treated with SK053. As 
presented in Figure 4C, the dimers could only be detected 
for PRDX1–4, which are functional dimers. Treatment 
with other thiol-reactive compounds, adenanthin and 
AW464, did not trigger dimer formation, suggesting that it 
is a unique feature of SK053 (Supplementary Figure S6).
SK053 crosslinks PRDX1 dimers via active site 
cysteine residues
The above results imply that SK053 binds to 
PRDX1–4 in lymphoma cells. In agreement, SK053 
inhibited PRDX1 activity and SK-bio bound recombinant 
human PRDX1 monomer and triggered dimer formation, 
however less efficiently than in cells (Supplementary 
Figure S7). To gain more insight into the binding of SK053 
to PRDX1, we docked SK053 to the PRDX1 model. 
During the catalytic cycle, the regions bearing active 
site Cys residues undergo substantial conformational 
rearrangements ([25, 26], Supplementary Figure S8A). 
Assuming that SK053 covalently binds to PRDX1 thiols, 
we first docked the inhibitor to the reduced PRDX1 variant 
[25]. However, in this conformation, the active site Cys 
residues are not easily accessible to the bulky inhibitor 
(data not shown). In contrast, the inhibitor fits well into 
the oxidized form [27]. The inhibitor docked with the 
best scores in the shallower pocket in the region around 
the resolving Cys173 (Figure 5A, Supplementary Figure 
S8B).
Considering the accumulation of covalent PRDX1 
dimers upon SK053 in lymphoma cells, we speculated 
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that the two catalytic Cys residues, Cys52 and Cys173, are 
both binding sites of SK053. To test this hypothesis, we 
generated constructs for the expression of V5-tagged human 
wild-type PRDX1 and a series of point mutated variants, 
in which Cys residues were substituted with Ala, including 
single catalytic Cys residues (C52A, C173A), double 
catalytic Cys (C52A/C173A), and the variant C83A, which 
has a mutation of the Cys residue outside the active site. The 
mutation of each of the catalytic Cys, but not the Cys83, 
abolished the formation of the V5-tagged homodimer, as 
Figure 2: Both PRDX1 and PRDX2 control the proliferation and survival of lymphoma cells. A. Raji-sub cells were 
treated with lentiviruses encoding two different PRDX1-specific shRNAs or control, non-targeting shRNA. After puromycin selection, the 
number of viable cells was evaluated in a hemocytometer for three consecutive days. At days 1 (d1) and 3 (d3) cells were collected, and the 
levels of PRDX1, PRDX2 were evaluated by immunoblotting. B. The level of cleaved PARP (clPARP) was assessed by immunoblotting. 
C. Raji cells were subjected to transduction with lentiviruses carrying PRDX2-specific shRNA and hygromycin resistance gene. After 6 
days of antibiotic selection, the cells were infected with lentiviruses encoding PRDX1-targeting shRNA2 and puromycin resistance genes. 
Following 3 days of puromycin selection, the number of viable cells was assessed with flow cytometry, by counting the PI-negative cells. 
Three days after puromycin selection, cells were collected and the levels of PRDX1 and PRDX2 were analyzed by immunoblotting. 
D. Levels of clPARP, P-ERK1/2, p21 were assessed at day 3 post selection by immunoblotting. DNA synthesis was assessed in Raji cells 
expressing PRDX1-specific shRNA2 (shPRDX1) and control cells expressing non-targeting shRNA (control shRNA) with the Click-iT 
EdU (5-ethynyl-2′-deoxyuridine) incorporation assay. Data show the % of EdU-positive cells, mean values from two independent repeats 
± SD, *P < 0.05. The cell cycle distributions in Raji cells expressing PRDX1-specific shRNA2 (shPRDX1) and control cells expressing 
non-targeting shRNA (control shRNA) were evaluated with a propidium iodide flow cytometry-based assay. The error bars indicate the 
SD (n = 2), *P < 0.05. E. Namalwa cells were subjected to sequential lentiviral transductions to downregulate PRDX1 and PRDX2, as 
described in C. and the number of viable cells was assessed in a hemocytometer for three consecutive days. The degree of PRDX1 and 
PRDX2 knockdown was assessed by immunoblotting in cells collected 3 days after puromycin selection.
Oncotarget1722www.impactjournals.com/oncotarget
detected with anti-V5 antibody (Figure 5B, left panel). 
Although heterodimers of V5-tagged PRDX1, and its native 
untagged form, could be detected for single active site Cys 
mutants, they were absent in the case of the double C52A/
C173A mutant. C83A variant behave like wild-type (Figure 
5B, right panel). These results confirmed the essential 
role of the two catalytic Cys residues in SK053-triggered 
crosslinking of PRDX1 dimers and allowed us to propose 
Figure 3: SK053 covalently binds to PRDX1 in Raji cells. A. Cytostatic/cytotoxic effects of SK053 on human BL cell lines and 
normal germinal center B cells (GC B cells). BL cell lines were incubated with SK053 for 48 h and subjected to a MTT viability assay. The 
LC
50
 was calculated in Graphpad Prism 5 by nonlinear regression dose-response analysis with variable slopes. The SEM was calculated 
based on two independent experiments. GC B cells isolated from human tonsils (n = 3) were isolated and cultured as described in Methods. 
Number of viable cells after 48 h treatment with SK053 was assessed using Muse™ Cell Analyzer (Merck Millipore). LC
50
 was calculated 
in Graphpad Prism 5, as described above for BL cell lines. B. Chemical structure of SK053, its biotinylated derivative SK-bio, and the 
inactive biotinylated analog devoid of the electrophilic center, SK-in. C. Raji-sub cells were incubated with SK-bio or SK-in for 2 h, lysed, 
and biotin-labeled proteins were affinity-purified on avidin-coated beads. Total protein was resolved by SDS-PAGE and visualized by 
silver staining. The arrow indicates the band that was excised and identified by mass spectrometry. D. Tandem mass spectra of the Cys-
173-containing peptide, HGEVCPAGWKPDGSDTIKPDVQK. The site of cysteine modification is marked with a star. The upper panel 
spectrum corresponds to a peptide modified with iodoacetamide (+57.021), with the parent ion m/z 802.731 and a charge 3+. The bottom 
panel presents the spectrum of a peptide in which cysteine bears an inhibitor (+466.225), with parent ion m/z 704.600 and a charge 4+. E. 
The same samples as in C. were subjected to immunobloting using antibodies specific to PRDX1 and β-actin (ACTIN).
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the mechanism of double thioalkylation of peroxidatic and 
resolving cysteines, presented in Figure 5C. We presume 
that similar mechanism occurs for all typical 2-Cys PRDXs.
SK053 triggers ROS accumulation, growth 
arrest and apoptosis
As SK053 inhibits PRDX1 catalytic activity, we next 
investigated the effects of SK053 on ROS homeostasis. As 
shown in Figure 6A and Supplementary Figure S9, SK053 
increased the levels of ROS in Raji cells in a time- and 
dose- dependent manner. Importantly, the accumulation 
of ROS was attenuated in cells that were pre-treated with 
pyruvate, a non-enzymatic hydrogen peroxide scavenger 
[28], as well as with catalase, an enzyme specifically 
removing hydrogen peroxide (Figure 6A). These data 
imply that hydrogen peroxide is a dominant ROS 
accumulated in cells incubated with SK053.
It is established that hydrogen peroxide induces 
phosphorylation of kinases, such as ERK1/2 and AKT 
[11, 12]. Indeed, in our study, treatment of Raji cells 
with SK053 triggered prolonged ERK1/2 and AKT 
phosphorylation (Figure 6B). It was previously reported 
that increased ROS due to PRDXs downregulation induced 
cell cycle arrest [29, 30]. Accordingly, SK053 significantly 
reduced DNA synthesis (Figure 6C) and triggered cell 
cycle arrest (Figure 6D). In addition, SK053 induced 
apoptosis, as evidenced by the occurrence of cleaved 
caspase-3 and PARP (Figure 6E) and the increase in the 
numbers of early and late apoptotic cells (Figure 6F). 
Pretreatment with pyruvate or ERK1/2 phosphorylation 
inhibitor, U0126, attenuated SK053-induced apoptosis 
(Figure 6F–6H). Taken together, these results demonstrate 
that SK053 inhibits cell proliferation, and, at higher doses, 
triggers apoptosis. Moreover, SK053-induced cell death 
is, at least to some extent, triggered by ERK1/2 signaling.
DISCUSSION
In this work, we identify PRDXs as a new, attractive 
therapeutic targets in BL. Particularly, we show that 
PRDX1 and PRDX2 are abundantly expressed in B 
cell-derived primary lymphoma cells and cell lines as 
well as that they promote lymphoma cell proliferation 
and survival. Moreover, we identify 2-Cys PRDXs as 
molecular targets for a new thiol-targeting compound, 
Figure 4: SK053 triggers the formation of covalent typical 2-Cys PRDXs dimers. Cells were cultured with SK053, biotinylated 
SK053 (SK-bio) or its inactive counterpart (SK-in), harvested and analyzed by immunoblotting using specific antibodies, as indicated on 
the left side of each blot. Bands labeled M migrated at ~ 22 kDa, a mass corresponding to the molecular weight of the peroxiredoxin 
monomer, and bands labeled D migrated at ~ 44 kDa, a mass corresponding to the molecular weight of the peroxiredoxin dimer. A. The 
concentration of SK-bio and SK-in was 55 μM (=LC
80
). B. Cells were cultured with the indicated concentrations of SK053 for 24 h. C. 10 
μM of SK053 was used, which is close to the LC
50
.
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SK053, which confirms druggability of PRDXs in 
lymphoma cells. We would like to emphasize that SK053, 
as a peptidomimetic, is not an optimal small molecule 
for further pursuing towards clinical trials. However, our 
mechanistic investigations provide evidence that double 
thioalkylation of active site cysteines is a novel, effective 
Figure 5: SK053 cross-links PRDX1 monomers via its active site cysteine residues, Cys52 and Cys173. A. Docking of the 
SK053 molecule to the binding pocket around Cys173 of the rat PRDX1 model (PDB code 1QQ2), in which all rat-specific amino acids 
were substituted to human-specific counterparts. Active site Cys residues, Cys52 and Cys173, are indicated in red. Distances between the 
sp2 carbon and Cys thiols are indicated with dashed black lines. Favorable hydrogen bonds are shown as blue dashed lines. B. HEK293T 
cells were transfected with a pLenti6-PRDX1-V5 plasmid encoding a V5-tagged, wild-type protein (WT), or protein variant with selected 
cysteines mutated to alanines. Twenty-four hours after transfection, 41 μM (~ LC
50
) SK053 (+) or DMSO (-) was added, and after an 
additional 24 h, the cells were harvested and analyzed by immunoblotting using anti-V5 and anti-PRDX1 antibodies. Note that on the 
PRDX1 immunoblot (right panel), the highest molecular weight band corresponds to the V5-tagged PRDX1 homodimer (Homo-D V5), 
the lowest to the untagged homodimer (Homo-D) and the two middle bands to the heterodimers (Hetero-D). C. Scheme presenting double 
thioalkylation of the active site Cys residues of dimeric 2-Cys PRDXs, resolving Cys (CR) and peroxidatic Cys (CP) with SK053.
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Figure 6: SK053 triggers ROS accumulation, cell cycle arrest and apoptosis. A. Raji cells were loaded with CM-H2-DCFDA dye and 
treated with SK053 for the indicated times or for 2 h with 100 μM H
2
O
2
, as a positive control. Two additional groups were included, in which Raji cells 
were pre-treated with 2 mM pyruvate (dark grey bar) or 100 μg/ml catalase (bar filled with horizontal lines) for 30 min and then exposed to 20 μM 
SK053 for 8 h. The green fluorescence intensity was evaluated by flow cytometry, and the ROS levels are presented as the fold change over untreated 
control. The mean values from two independent repeats ± SD are shown, *P < 0.05, **P < 0.001. B. Immunoblotting of Raji cells treated with 10 μM 
SK053 or 50 μM hydrogen peroxide for the indicated time. C. The rate of DNA synthesis was assessed with the Click-iT EdU incorporation assay. 
Data show the % of EdU-positive cells, mean values from two independent repeats ± SD, *P < 0.05, and **P < 0.001 versus untreated control cells. 
D. The cell cycle distribution after treatment of Raji cells with SK053 was analyzed using a propidium iodide flow cytometry-based assay. The error 
bars indicate the SD (n = 2), *P < 0.05 versus untreated control cells. E. Raji cells were treated with SK053 for the indicated time, lysed and analyzed 
by immunoblotting. F. Apoptosis was evaluated in Raji cells treated for 24 h with SK053, or pre-treated with 2 mM pyruvate for 30 min and then 
incubated with SK053 for 24 h. The numbers of early and late apoptotic cells were assessed using annexin V and propidium iodide staining, followed 
by flow cytometry analysis. The mean values are presented ± SD (n = 2), *P < 0.05. G. Raji cells were treated and analyzed as described in panel F. 
but 30 μM U0126 was used for pre-treatment, instead of pyruvate. H. Immunoblotting of Raji cells treated with SK053 +/− U0126.
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strategy to inhibit dimeric PRDXs and may guide the 
design of a new class of anti-lymphoma therapeutics.
Peroxiredoxins have been studied in different 
tumors; however, their roles vary [8, 17]. Interestingly, 
downregulation of TRX inhibitory protein VDUP1, and 
upregulation of PRDX3 and PRDX4, correlated with poor 
prognosis of DLBCL patients, indicating tumor-promoting 
role of TRX-like enzymes in lymphomas [31]. Our results 
support this finding. Specifically, we demonstrate that 
PRDXs are highly expressed in human tumor B cell-
derived primary lymphoma cells and cell lines (Figure 1, 
Supplementary Figure S1, Supplementary Tables S1 and 
S2). Furthermore, in a model of BL cell lines, we show 
that concomitant downregulation of PRDX1 and PRDX2 
diminishes the growth rate of lymphoma cells (Figure 
2, Supplementary Figure S2). These observations are in 
agreement with previously published data that PRDX 
knockdown decreases cell proliferation and triggers cell 
cycle arrest and senescence in murine embryonic cells as 
well as in human glioma cells [29, 30, 32]. All of these 
findings provide a new information that, in BL cells, both 
PRDX1 and PRDX2 promote cell growth and proliferation, 
with a functional overlap between these two enzymes.
Lymphoma cells are characterized by a rapid 
proliferation rate and increased levels of ROS, therefore they 
require strict control of red-ox homeostasis [1]. Dozens of 
enzymes account for red-ox homeostasis, and some of them 
are redundant. Recent studies revealed that deletion of one 
antioxidant enzyme triggers compensatory upregulation of 
the other and that inhibition of both glutathione and TRX-
based antioxidant systems synergistically kills cancer cells 
[4]. Here we present that the small-molecule inhibitor, 
SK053, which was previously shown to inhibit TRX-TRXR 
system, has broader specificity towards other TRX-like 
proteins. Using the biotin affinity labeling approach, we 
identified dimeric 2-Cys PRDXs as targets for SK053 (Figure 
3). We did not succeed to isolate TRX1 and TRXR1 by biotin 
affinity labeling as covalent SK053 targets (Supplementary 
Figure S5). Possibly, their binding may not be preserved 
during the isolation and separation of biotinylated 
proteins. Indeed, using a different procedure, involving 
the incubation of SK-bio with Raji cell lysates, we could 
isolate both TRX1 and TRXR1 as SK-bio-binding proteins 
(Supplementary Figure S10); however, we consider the latter 
approach less physiologically relevant. The affinity labeling 
has proven effective for a small-molecule target identification 
in multiple instances [18, 33]; nevertheless, it has some 
limitations. Therefore, we present evidence from additional 
experiments confirming that dimeric 2-Cys PRDXs are 
SK053 targets in lymphoma cells. Foremost, only PRDX1-
4, which are functional dimers, undergo dimer crosslinking 
upon treatment with SK053. The dimer formation is dose-
dependent and proceeds in the time during incubation with 
SK053, suggesting that the inhibitor is preserved for up to 
24 h in cells (Figure 4A). Moreover, we show that double 
thioalkylation occurs at the active site Cys residues (Figure 
5), implying that SK053 blocks PRDX enzymatic activity. 
Indeed, SK053 binds to recombinant human PRDX1 and 
inhibits its activity in an in vitro assay (Supplementary 
Figure S7). Consistently, in Raji cells SK053 triggers ROS 
accumulation, ERK1/2 and AKT phosphorylation, kinase 
signaling that is typically induced in response to hydrogen 
peroxide (Figure 6A, 6B Supplementary Figure S9). At 
a lower concentration (5 μM), SK053 causes reversible 
inhibition of DNA synthesis and cell cycle arrest (Figure 6C, 
6D). At concentrations above 10 μM, SK053 abrogates DNA 
synthesis and triggers apoptosis (Figure 6E, 6F). Interestingly, 
pretreatment with the inhibitor of ERK1/2 activator, U0126, 
blocks the phosphorylation of ERK1/2 and attenuates SK053-
induced apoptosis, implicating a role for ERK1/2 signaling 
in SK053-induced lymphoma cell death (Figure 6G, 6H). 
Canonically, Ras-Raf-MEK1-ERK1/2 signaling stimulates 
tumor cell proliferation; however, it may also mediate cell 
death, including oxidative stress-induced apoptosis [34].
SK053, unlike other thiol-reactive inhibitors 
adenanthin and AW464, triggers crosslinking of PRDX1–4 
dimers (Supplementary Figure S6). Our studies with V5-
tagged PRDX1 revealed that the thioalkylation reaction 
involves catalytic cysteines (Figure 5). Indeed, these 
residues approach one another to form a disulfide bond 
in the course of catalysis. During the catalytic cycle, 
peroxiredoxins undergo substantial conformational 
rearrangements, particularly within the loop bearing 
resolving Cys (Supplementary Figure S8A). Our attempts 
to dock SK053 to the rat PRDX1 imply that the first 
thioalkylation occurs at the resolving Cys173. Intact 
SK053 fits better in the shallower pocket around Cys173. 
In the model with SK053 docking to the PRDX1 dimer, 
the unsaturated carbon localizes at a distance of 3 Å from 
the Cys173 sulfur. In addition, the aromatic acyloxy group 
is placed in a positively charged environment, which 
can support its dissociation and formation of the second 
electrophilic center (Figure 5A). Accordingly, MS analysis 
of tryptic peptides derived from the biotin affinity purified 
PRDX1 revealed the modification of the resolving Cys by 
the mass of 466 Da, which corresponds to the inhibitor 
part after the elimination of the acyloxy group (Figure 
3C). It is not entirely clear how the second thioalkylation 
occurs. In lymphoma cells, the crosslinked dimers are 
barely detectable after 2 h of incubation with SK053 and 
they gradually accumulate over a period of at least 24 h, 
showing that the process is slow in cells (Figure 4) and even 
less efficient in vitro (Supplementary Figure S7B). This 
may indicate that structural rearrangements, which may 
also involve partner protein interactions, are necessary for 
the second thioalkylation step. This is plausible, especially 
considering increased oxidative stress in cells treated with 
SK053. Structural studies have revealed that oxidation of 
peroxidatic Cys triggers local unfolding and major structural 
rearrangements of the regions around catalytic cysteines 
[25]. All these results demonstrate that double thioalkylation 
of catalytic cysteines is a novel strategy to inhibit dimeric 
PRDXs and provide a mechanistic basis for the design of a 
new class of dimeric 2-Cys PRDXs inhibitors.
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In summary, we present that lymphoma cells 
abundantly express TRX-like antioxidant proteins. 
Furthermore, we demonstrate that peptidomimetic small-
molecule SK053 covalently binds dimeric 2-Cys PRDXs 
in human BL cell lines. Importantly, our findings indicate 
that PRDX1 and PRDX2 have complementary growth-
supporting functions in a BL model in vitro. Based on these 
findings, we conclude that targeting TRX-like antioxidant 
proteins may be considered a promising approach to 
therapy of BL. At the same time, our results suggest that 
targeting a single PRDX may be insufficient in this disease 
and pinpoint the need for the development of pan-PRDX 
inhibitors with a prospective therapeutic use.
MATERIALS AND METHODS
Chemicals
SK053 was synthesized as described in [20], AW464 
(7a) as described in [35]. The synthesis of biotinylated 
SK053 analogue (SK-bio) and its inactive counterpart 
(SK-in) is described in the Supplementary Methods. 
Adenanthin was purchased from Faces Biochemical Co., 
Wuhan, China and U0126 from Selleckchem, USA.
Cell culture
Human BL cell lines (RAJI, Ramos, BJAB, Daudi, 
and Namalwa), B-cell chronic lymphocytic leukemia 
(Mec-1), DLBCL (DHL-4, DHL-6, Ly4, Ly7, Ly10, Ly1, 
and U2932) and human embryonic kidney (HEK293T) 
cells were purchased from ATCC. The Raji-sub cell line 
is a complement-sensitive sub-strain of Raji [24]. The 
authentication of the Raji-sub cell line was confirmed by 
genotyping (IdentiCell, Denmark). Cells were cultured 
in DMEM (HEK293T) or RPMI-1640 medium (all 
other cell lines) supplemented with 10% heat-inactivated 
fetal bovine serum and antibiotic at 37°C, 5% CO
2
, in a 
humidified atmosphere. In all experiments, control groups 
were treated with vehicle (DMSO).
Isolation and culture of germinal center B cells
Human tonsils were derived from children 
undergoing tonsillectomy (n = 3). Their use was approved 
by the Ethics Committee at the Institute of Physiology 
and Pathology of Hearing, Warsaw, Poland. After 
resection, tonsils were cut into small pieces and incubated 
in the RPMI medium supplemented with collagenase 
and DNase for 30 min at 37°C with gentle shaking and 
filtered through 70 μm cell strainer. After washing in 
PBS, mononuclear cells were isolated with Histopaque 
1077 density gradient and subjected to CD19 negative 
selection using EasySep™ Human B Cell Enrichment 
Kit (STEMCELL Technologies). The isolated B cells 
were stained with anti-CD20-PE and anti-CD38-FITC 
antibodies and CD20+/CD38+ germinal center B cells 
(GC B cells) were separated by fluorescence-activated cell 
sorting using FACSAria III.
For co-culture experiments, HT-1080 cells 
expressing human CD40L were incubated with mitomycin 
C (10 μg/ml, Sigma Aldrich) for 3 h, and seeded into 96-
well plates, 1 × 104 cells per well. Next day, when HT-
1080 cells were attached, the medium was removed and 
GC B cells were added, 1 × 105 cells per well, in RPMI full 
medium supplemented with 25 ng/ml IL-21 (Peprotech). 
To assess SK053 cytostatic/cytotoxic effects, cells in co-
culture were incubated with SK053 in a concentration 
range 5–80 μM for 48 h. The numbers of viable cells 
were assessed with Muse™ Cell Analyzer, using Count 
&Viability Reagent (Merck Millipore). The LC
50
 was 
calculated in Graphpad Prism 5 by nonlinear regression 
dose-response analysis with variable slopes.
Affinity isolation of biotinylated proteins
Raji-sub or Raji cells were cultured in a serum-
free RPMI medium in the presence of 100 μM SK-bio or 
SK-in, with 2 × 107 cells in each group. After two hours, 
the cells were harvested, lysed, and biotinylated proteins 
were isolated as described in [19]. The protein band that 
migrated around 20 kDa was excised from the gel and 
analyzed by MS. Alternatively, the eluates were subjected 
to immunoblotting.
Mass spectrometry
LC-MS analysis of gel slices was conducted as 
described in [36]. The raw data were pre-processed with 
Mascot Distiller software (v. 2.3, Matrix Science) and 
obtained peak lists were searched against the database 
of human protein sequences from SwissProt combined 
with its randomized version (40464 sequences) using 
Mascot search engine (version 2.4, 8-processors onsite 
license) (Matrix Science) with the following search 
parameters: enzyme specificity – semi-trypsin, missed 
cleavages – 1, variable modifications – oxidation (M), 
carbamidomethylation (CK), SK053(C), peptide mass 
tolerance – ± 20 ppm, fragment mass tolerance – ± 0.6 
Da. Decoy option in Mascot was activated in order 
to assure the false discovery rate below 1%, and the 
resulting Mascot score threshold of 63 was applied to 
results.
MTT assay
Cells were seeded into 96-well plates at a density of 
2 × 104 per well and treated with investigated compounds 
in a final volume of 200 μl. After 48 hours, MTT assay 
was performed as described in [21].
ROS assessment
Cells were loaded with CM-H2-DCFDA (Molecular 
Probes, USA) according to manufacturer’s protocol, using 
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1 μM dye concentration for 30 min at 37 °C. Next, labeled 
cells were incubated with SK053 or H
2
O
2
 in a culture 
medium at 37 °C, washed in PBS and the intensity of 
green fluorescence was analyzed in BD Accuri C6 Flow 
Cytometer (BD Biosciences, USA).
Immunoblotting
Cells were subjected to drug treatment at a density 
of 0.1–0.2 mln/ml. Cell lysis, protein concentration 
measurement and immunoblotting was performed as 
described in [21]. Antibodies used: Cell Signalling: 
cleaved PARP - 5625, caspase 3 - 9662, p21 Waf1/Cip1 
– 2947, biotin HRP-linked – 7075, Akt1 - 2967, phospho-
Akt (Thr308) – 2965, phospho-p44/42 MAPK (P-ERK1/2) 
(Thr202/Tyr204) – 9101, p44/42 MAPK (ERK1/2) – 9107, 
TRX1 - 2429; Sigma-Aldrich: PRDX1 - HPA007730, 
PRDX6 - HPA006983, β-actin-HRP – A3854; Abcam: 
PRDX2 - EPR5155; AbFrontier: PRDX3 - LF-MA0044, 
PRDX4 - LF-MA0014, PRDX5 - LF-MA0002, Life 
Technologies: V5 - R96025; Santa Cruz Biotechnology 
Inc.: TRXR1 – sc-20147, Enzo Life Sciences: CRT - ADI-
SPA-600.
Site-directed mutagenesis
The cysteine-to-alanine mutations were introduced 
to pLenti6/V5-DEST-PRDX1 using QuikChange XL Site-
Directed Mutagenesis Kit (Agilent Technologies, USA) 
according to manufacturer’s instruction. The primers are 
provided in Supplementary Table S3. Mutations were 
confirmed by DNA sequencing.
DNA synthesis
To evaluate the rate of DNA synthesis, for the last 
hour of incubation with SK053, 5-ethynyl-2′-deoxyuridine 
(EdU) was added to a final concentration of 50 μM. Next, 
cells were fixed, permeabilized and labeled according to 
Click-iT® EdU Alexa Fluor® 488 Imaging Kit protocol 
(Life Technologies, USA) and the number of EdU-positive 
cells was assessed by flow cytometry.
Cell cycle
Cells treated with SK053 were washed with PBS 
and fixed in 70% ethanol at -20 °C overnight. Next, cells 
were washed twice with PBS, and incubated in propidium 
iodide (50 μg/ml) containing 200 μg/ml RNase A at 
37 °C for 30 min. DNA content was analyzed by flow 
cytometry and FlowJo software. Cell cycle distribution 
was determined from 104 cells using Watson mathematical 
model with constraints set on the vehicle control (DMSO). 
The obtained results were further normalized using below 
formula so percentages of cells in each phase add up to 
100%: normalized proportion of a phase= (proportion of a 
phase/sum of all proportions) x 100%.
Apoptosis
Apoptosis was evaluated using Annexin V 
Apoptosis detection kit (eBioscience, USA), according to 
manufacturer’s protocol.
Real-time PCR
The RNA extraction, cDNA isolation and RT-PCR 
assay was performed as previously described [16].
Modeling and ligand docking
PRDX1 models with point mutations were prepared 
based on homology modeling procedures, using Modeller 
[37] and evaluated with MetaMQAP [38] and PROQ 
[39]. Protein structures superpositions were prepared 
with Swiss-PDBViewer [40]. Figures were prepared with 
PyMOL 1.5 (Schrödinger). For docking procedures we 
selected crystal structures-derived models (PDB codes 
1QQ2 and 2Z9S) and corresponding models with point 
mutations, with all rat-specific residues substituted with 
human equivalents. Docking simulations were carried 
out with Surflex-Dock 2.6 software [41] based on the 
“anchor-and-grow” algorithm for optimized structures 
of small molecules. We used elNémo web server [42] to 
calculate proteins normal modes. Files with coordinates 
are available in Supplementary Data.
Immunohistochemistry (IHC)
Lymph nodes from 4 patients with reactive follicular 
hyperplasia and tissue sections from gastric mucosa and 
tumors of the thigh, neck and thyroid gland from 4 patients 
with BL were evaluated. All individuals gave informed 
consent and the study was approved by the Institute of 
Hematology and Transfusion Medicine Ethics Committee. 
Tissue biopsies of the patients were histopathologically 
examined to establish a diagnosis according to 2008 WHO 
classification. Tissue biopsies were fixed in 10% formalin, 
routinely processed and stained with hematoxylin and 
eosin. Immunohistochemistry was performed using the 
following antibodies: PRDX1 (Sigma-Aldrich, dilution 
1:150, pH = 9.0) and PRDX2 (GeneTex, clone EPR5154, 
dilution 1:200, pH = 9.0). Staining was performed 
according to the manufacturer’s instructions. The 
EnVision System (Dako) was used for detection. Positive 
controls included human tonsils (PRDX1) and human 
prostatic hyperplasia (PRDX2). The negative (isotype) 
controls were generated with ready to use FLEX Negative 
Control Mouse (cocktail of mouse IgG1, IgG2a, IgG2b, 
IgG3 and IgM; code No IR750; Dako). Samples were 
reviewed for the expression of lymphoid cells by MPS. 
Appropriate cellular localization for immunostaining was 
membrane and cytoplasmic for PRDX1 and PRDX2. 
All photographs were taken using DP72 Olympus BX63 
microscope camera (Olympus, Japan).
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Gene expression analysis
To examine expression levels of the genes involved 
in the red-ox pathway in the selected populations of B cells 
we accessed the E-GEOD-12453 data set [22] deposited 
in the ArrayExpress database [43]. Briefly, the raw (CEL) 
data was normalized using the robust multiarray average 
(RMA) procedure using a custom CDF environment 
[44] in order to collapse the features to the Entrez gene 
level. The normalized data was then mean-centered and 
scaled. The significance for each gene to differentiate the 
respective B cell classes was computed using analysis of 
variance and the differences in expression between the 
normal B cells and DLBCL and BL samples, respectively, 
was done using the Mann-Whitney non-parametric test. 
All of the statistical procedures were done in R.
Downregulation of PRDX1 and PRDX2
PRDX1 was downregulated using pLKO.1-puro 
vector-based lentiviral transduction particles purchased 
from Sigma-Aldrich, USA. To downregulate PRDX2, 
plasmids encoding PRDX2-specific shRNA as well 
as hygromycin resistance gene were purchased from 
ATCGbio Life Tech Inc., USA. Lentiviruses production 
and transductions were performed according to 
manufacturer’s instructions. Targeting sequences and 
experimental details are provided in Supplementary 
Methods.
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